In histopathology, pathologists assess patient biopsies and tissue resections to study the presence and/or grade of a disease, but also for selecting personalized treatment and monitoring. With respect to other diagnostic technologies, tissue analysis is more invasive, but at the same time provides much higher resolution.

Currently, pathologists assess tissues under a microscope, leading to diagnoses affected by subjective judgment and intra- and inter-observer variability. This is due to the difficulty of the process. The staining intensity in the tissue, as well as the morphological and cellular architecture indicate cancer and many diseases.

We aim to develop image ana­ly­tics that can quan­ti­fy path­o­gen­esis in a high-through­put, bias-free and ro­bust way.

—Maria Gabrani, IBM scientist

However, disease susceptibility and progression is a complex, multifactorial molecular process. Diseases such as cancer exhibit tissue and cellular heterogeneities, which impedes differentiation between different stages or types of cell formations. At the same time, the procedure is time-consuming and low-throughput, strained by the number of tissue samples generated per day.

Emerging initiatives to bring hospitals into the digital era are using bright-field and fluorescence scanners to convert glass slides of tissue specimens and needle biopsies into virtual microscopy images of very high quality, enabling digital image analysis.

Our focus

At IBM Research – Zurich, we are focusing on the analysis of digitized histopathology and molecular expression images, as well as cytology images. Imaging tissue specimens is a powerful tool to extract quantitative metrics of phenotypic properties while preserving the morphology and spatial relationship of the tissue micro­environment.

Novel staining technologies such as immuno­histo­chemistry (IHC) and in situ hybridization (ISH) further improve the evidencing of molecular expression patterns by means of multicolor visualization.

Such techniques are thus commonly used for predicting disease susceptibility and stratification as well as for selecting treatment and monitoring. However, translating molecular expression imaging into direct health benefits has been slow.

Two major factors contribute to that. On the one hand, disease susceptibility and progression is a complex, multifactorial molecular process. The tissue and cell heterogeneity exhibited by diseases such as cancer occur most prominently between inflammatory response and malignant cell transition.

On the other hand, the relative quantification of the selected features in stained tissue samples is ambiguous, tedious and time-consuming, and therefore prone to technician and clerical errors. This in turn leads to intra- and interobserver variability and low throughput.

At IBM Research – Zurich, we are developing advanced image analytics to address both the above limitations. Our aim is to transform the analysis of stained tissue images into a high-throughput, robust, quantitative and data-driven science.

Value proposition

 

Patient

  • Higher accuracy
  • Fewer misdiagnoses
  • Better outcomes

Pathologist

  • Case ordering
  • Efficiency
  • Surgery assistance

Hospital

  • Case ordering
  • Less diagnostic variability
  • Lower costs

Payer

  • Second-opinion enablement
  • Lower costs

Cost savings

$17.8 million

Projected 5-year total cost savings for a large, academic-based healthcare organization upon fully implementing a DP system

$3 million

Annual savings of FEDEX costs for a diagnostics services provider with a DP system that analyzes 4,000–5,000 slides daily.

Complexities

card_3

Diagnostic complexity


  • Misdiagnosis
  • Over-diagnosis
  • Over-treatment
card_3

Phenotypic complexity


  • Tissue/tumor/cell/molecular heterogeneity
  • Cell plasticity
card_3

Process complexity


  • Capturing induced ambiguity
  • Time consuming
  • Tedious
  • Bias prone
card_3

Disease complexity


  • Molecular
  • Cellular/Tissue
  • Historical
  • Environmental

Projects

card_3

Prostate cancer stratification

card_3

Breast cancer tumor proliferation estimation

card_3

Colorectal cancer metastasis study

card_3

Tissue heterogeneity quantification

card_3

Protein signature quantification

card_3

Stained image quality metric and sensitivity to staining parameters estimation

Ask the expert

Maria Gabrani

Maria Gabrani
IBM Research scientist

card_3

Collaboration

We base our technology development and validation on data, labels and domain insights from experts in the field through numerous collaborations with university hospitals and other partners, such as the University Hospital Zurich, Switzerland, and Humanitas University Hospital, Italy, as they are nicely described in the TV interviews.

Journals

  1. E. Zerhouni et al.
    Computational Processing of Histological Images,”
    ERCIM News 108, 14-15, 2017.
  2. Q. Zhong, et al.
    Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity”,
    Scientic Reports 6(24146), 2016.
  3. E. Zerhouni, B. Prisacari, Q. Zhong, P. Wild, M. Gabrani,
    Big Data Takes on Prostate Cancer,”
    ERCIM News 104, 34-35, 2016.

Conferences

  1. E. Zerhouni, et al.,
    Heterogeneity Characterization of Immunohistochemically Stained Tissue using Convolutional Autoencoder,”
    Proc. SPIE 10140, Medical Imaging 2017: Digital Pathology, 101400P, 2017.
  2. E. Zerhouni, et al.,
    “Wide Residual Networks for Mitosis Detection,”
    Proceedings of IEEE 14th International Symposium on Biomedical Imaging (ISBI), 2017.
  3. E. Zerhouni, et al.,
    “Disease Grading of Heterogeneous Tissue using Convolutional Autoencoder,”
    Proceedings of IEEE 14th International Symposium on Biomedical Imaging (ISBI), 2017.
  4. E. Zerhouni, B. Prisacari, Q. Zhong, P. Wild, M. Gabrani,
    Deciphering protein signatures using color, morphological, and topological analysis of immunohistochemically stained human tissues,”
    Proceedings of SPIE, Vol. 9791, 97910T, 2016.
  5. E. Zerhouni, B. Prisacari, Q. Zhong, P. Wild, M. Gabrani,
    A computational framework for disease grading using protein signatures,”
    13th IEEE International Symposium on Biomedical Imaging (ISBI), Prague, Czech Republic, 1401-1404, 2016.

Presentations

  1. E. Zerhouni, B. Prisacari, Q. Zhong, P.J. Wild, M, Gabrani,
    “A Computationaly extracting unique protein signatures for IHC assays per grade and protein for personalized treatment,”
    DGP 2016, Berlin, Germany, May 19-21, 2016.
  2. M. Kolectou, M. Gabrani, T. Guo, Q. Zhong, U. Wagner, R. Aebersold, P.J. Wild, M, Rodriguez,
    “A Computational framework for systems pathology of prostate cancer,”
    DGP 2016, Berlin, Germany, May 19-21, 2016.
  3. M. Kolectou, M. Gabrani, T. Guo, Q. Zhong, U. Wagner, R. Aebersold, P.J. Wild, M. Rodriguez,
    “A Computational framework for systems pathology of prostate cancer,”
    Systems Biology of Human Diseases, Boston, MA, USA, June 14-16, 2016.
  4. Q. Zhong, M. Gabrani, T. Guo, P.J. Scher, R. Aebersold, H. Moch, P.J. Wild,
    “Computational profiling of heterogeneity reveals high concordance between morphology- and proteomics based methods in prostate cancer,”
    DGP 2015, Frankfurt, Germany, May 28-31, 2015